ECSP17058071A - Derivados de tetrahidropiranil benzamida - Google Patents

Derivados de tetrahidropiranil benzamida

Info

Publication number
ECSP17058071A
ECSP17058071A ECIEPI201758071A ECPI201758071A ECSP17058071A EC SP17058071 A ECSP17058071 A EC SP17058071A EC IEPI201758071 A ECIEPI201758071 A EC IEPI201758071A EC PI201758071 A ECPI201758071 A EC PI201758071A EC SP17058071 A ECSP17058071 A EC SP17058071A
Authority
EC
Ecuador
Prior art keywords
tetrahydropyranil
benzamide derivatives
compounds
benzamide
derivatives
Prior art date
Application number
ECIEPI201758071A
Other languages
English (en)
Inventor
Haizhen Zhang
Jingye Zhou
zhi long Hu
Tianwei Ma
Lian Zhu Liu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP17058071A publication Critical patent/ECSP17058071A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula siguiente: en donde R, R1-R3 son como se describen en la presente; métodos para tratar pacientes por diabetes usando los compuestos, y procesos para preparar los compuestos.
ECIEPI201758071A 2015-03-03 2017-09-01 Derivados de tetrahidropiranil benzamida ECSP17058071A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/073563 WO2016138631A1 (en) 2015-03-03 2015-03-03 Imidazo benzamide compounds

Publications (1)

Publication Number Publication Date
ECSP17058071A true ECSP17058071A (es) 2017-10-31

Family

ID=56849060

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201758071A ECSP17058071A (es) 2015-03-03 2017-09-01 Derivados de tetrahidropiranil benzamida

Country Status (24)

Country Link
US (1) US10196385B2 (es)
EP (1) EP3265460A4 (es)
JP (1) JP2018507232A (es)
KR (1) KR20170106483A (es)
CN (1) CN107406436B (es)
AU (1) AU2016228055B2 (es)
BR (1) BR112017015448A2 (es)
CA (1) CA2975413A1 (es)
CL (1) CL2017002148A1 (es)
CO (1) CO2017008721A2 (es)
CR (1) CR20170354A (es)
DO (1) DOP2017000196A (es)
EA (1) EA201791745A1 (es)
EC (1) ECSP17058071A (es)
IL (1) IL253405A0 (es)
MA (1) MA41641A (es)
MX (1) MX2017011087A (es)
PE (1) PE20171650A1 (es)
PH (1) PH12017501560A1 (es)
SG (1) SG11201706718RA (es)
SV (1) SV2017005520A (es)
TN (1) TN2017000372A1 (es)
WO (2) WO2016138631A1 (es)
ZA (1) ZA201704948B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014337A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
MX2020009372A (es) 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002904A1 (es) 2006-10-10 2008-06-06 Amgen Inc Soc Organizada Bajo Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2404896A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Cyclohexane derivative having npy y5 receptor antagonism
EP2523558A4 (en) * 2010-01-15 2013-06-19 Merck Sharp & Dohme BETA-CARBOLINE OXADIAZOLE DERIVATIVES AS ANTIDIABETIC COMPOUNDS
EP2686312B1 (en) * 2011-03-14 2016-08-31 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound

Also Published As

Publication number Publication date
EP3265460A1 (en) 2018-01-10
IL253405A0 (en) 2017-09-28
DOP2017000196A (es) 2017-09-15
WO2016138631A1 (en) 2016-09-09
CR20170354A (es) 2017-09-05
ZA201704948B (en) 2019-02-27
EP3265460A4 (en) 2018-08-08
BR112017015448A2 (pt) 2018-01-30
EA201791745A1 (ru) 2018-01-31
US20180194755A1 (en) 2018-07-12
KR20170106483A (ko) 2017-09-20
CN107406436B (zh) 2021-02-26
MX2017011087A (es) 2017-11-10
PH12017501560A1 (en) 2018-02-05
SV2017005520A (es) 2018-08-27
JP2018507232A (ja) 2018-03-15
CO2017008721A2 (es) 2018-01-05
PE20171650A1 (es) 2017-11-13
SG11201706718RA (en) 2017-09-28
CL2017002148A1 (es) 2018-04-13
WO2016138821A1 (en) 2016-09-09
AU2016228055B2 (en) 2018-06-07
CA2975413A1 (en) 2016-09-09
TN2017000372A1 (en) 2019-01-16
AU2016228055A1 (en) 2017-08-17
US10196385B2 (en) 2019-02-05
CN107406436A (zh) 2017-11-28
MA41641A (fr) 2018-01-09

Similar Documents

Publication Publication Date Title
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
BR112017007014A2 (pt) derivados de benzotiofenila substituídos como agonistas do gpr40 para o tratamento de diabetes tipo ii
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
CY1124164T1 (el) Καινοτομος παρασκευη και κρυσταλλωση της ιοσιμενολης
DOP2016000211A (es) Pirazinas moduladoras de gpr6
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016011899A2 (pt) Processo para preparação de 5-fluoro-1h-pirazóis
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112018070345A2 (pt) processo para a preparação de derivados de 4-aminoindano e amidas de aminoindano relacionadas
ECSP17058071A (es) Derivados de tetrahidropiranil benzamida
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina
BR112017018992A2 (pt) processo de preparação de derivados de fenilisoxazolina substituída